CannabisNewsBreaks

TuesdayJan 09, 2018 10:08 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Responds to Cole Memo Repeal

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning issued a follow-up statement to the memorandum issued by Attorney General Jeff Sessions on January 4, 2018, concerning marijuana enforcement and the repeal of the Cole Memo. In the update, Veritas noted that the AG’s decision largely relates to the recreational cannabis marketplace, in which individual states have allowed sales over the last 24 months. Conversely, the company notes, it does not affect the medical cannabis marketplace. As such, Veritas intends to build on its commitment to advancing the science of medical cannabis…

Continue Reading

MondayJan 08, 2018 12:34 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Recaps 2017 Highlights

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, this morning announced the release of a 2017 year-end summary penned by CEO Chris Bunka. The release highlights what Bunka refers to as Lexaria’s “busiest and most productive” year to date, including details about the company’s progress toward strengthening its balance sheet, ongoing research and development efforts related to its patented DehydraTECH™ absorption and palatability enhancing technology, its preparations for increased demand in both Californian and Canadian markets and its ongoing efforts to strengthen its intellectual property portfolio. Bunka…

Continue Reading

MondayJan 08, 2018 12:28 pm

CannabisNewsBreaks – NeutriSci International Inc. (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) Enters Research and Development MOU with Scientus Pharma Inc.

NeutriSci International (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9) this morning announced that it has entered into a major research and development (R&D) Memorandum of Understanding (“MOU”) with Scientus Pharma Inc. In accordance of the terms set forth in the MOU, the two companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for current retail distribution networks throughout Canada. "This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant…

Continue Reading

FridayJan 05, 2018 10:19 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Names New Chief Marketing Officer

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced its appointment of Sung Kang as its new chief marketing officer, effective January 8, 2018. Kang brings more than 17 years of marketing experience to the ABcann team, having previously served as the head of marketing for the Mike’s Beverage Company, Canada’s leading ready-to-drink and cider business. “Sung is a great addition to the leadership team,” Barry Fishman, CEO of ABcann, stated in the news release. “We believe his marketing expertise combined with his experience in the alcohol and consumer health industries will prove invaluable to ABcann’s future growth. He…

Continue Reading

ThursdayJan 04, 2018 11:35 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Begins Trading on OTCQX Best Market

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, this morning announced that Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has qualified to trade on the OTCQX® Best Market. Subsequently, Lexaria has upgraded from the OTCQB® Venture Market, beginning today. “Lexaria has made notable progress over the past twelve months in all aspects of its business, and will receive even more recognition by upgrading to OTCQX,” Chris Bunka, chief executive officer of Lexaria, stated in the news release. “Lexaria…

Continue Reading

ThursdayJan 04, 2018 11:31 am

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Northern Lights Subsidiary Making Strides Toward Sales License

Premium cannabis lifestyle brand DOJA Cannabis Company’s (CSE: DOJA) (OTC: DJACF) wholly owned subsidiary, Northern Lights Marijuana Company, is a Health Canada licensed cannabis producer on the track to gain a Sales License. An article discussing the company reads: “DOJA’s initial cannabis harvest, produced under the Access to Cannabis for Medical Purposes Regulations (ACMPR) license held by its subsidiary, Northern Lights Marijuana Company, will be inspected by Health Canada regulators as the last step before a Sales License can be awarded. Once DOJA passes this major milestone and receives its Sales License, the company can begin selling cannabis and position…

Continue Reading

WednesdayJan 03, 2018 11:49 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Highlights Hidden Value of Wide-ranging DehydraTECH™ Patent

Based in Kelowna, British Columbia, Canada, food bioscience company Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is a technology disruptor for edible CBD. An article discussing this reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka said in an audio interview with the Uptick Newswire Podcast (http://cnw.fm/Refc4) that the company was not only surprised by how quickly it received its patent for DehydraTECH™; it was also surprised by the broadness of the patent awarded for its utilization in other sectors, which it had expected in 2018 and 2019. The company believes that the new patent has locked up the…

Continue Reading

TuesdayJan 02, 2018 10:32 am

CannabisNewsBreaks – ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Receives Cannabis Oil Production License from Health Canada

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) this morning announced that it has been licensed by Health Canada to produce medical cannabis oils. Per the update, Health Canada will conduct a final inspection when ABcann has saleable extracted finished products. ABcann expects to complete this process in the first quarter of 2018. “Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed,” Barry Fishman, CEO of ABcann, stated in the news release. “The expansion and innovation of our product lines…

Continue Reading

TuesdayJan 02, 2018 9:44 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Adds Dr. Brian O’Connor to Advisory Board

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced the addition of Dr. Brian O’Connor, a consultant in respiratory medicine, to its advisory board. Per the update, O’Connor is a clinical expert in the areas of asthma, chronic obstructive pulmonary disease (“COPD”), allergic disease and lung cancer. He is also an active clinical researcher committed to investigating new treatment strategies in airways disease. “Dr. O’Connor brings a great reputation of clinical excellence and scholarly research,” Dr. Lui Franciosi, CEO of Veritas, stated in the news release. “He will advise us on…

Continue Reading

FridayDec 29, 2017 9:44 am

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) Visits Clinical Trial Facility in San Juan, Puerto Rico

Emerging-stage pharmaceutical and IP development company Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) this morning announced that it has completed a prestudy visit of the Fundación de Investigación (“FDI”) facilities in San Juan, Puerto Rico. Per the release, this will be the site where the company’s research arm, Cannevert Therapeutics Ltd. (“CTL”), will be conducting its first human study of CTL-X, a cannabis strain targeting the pain management market. Speaking about the FDI clinical trial facility in this morning's update, Veritas CEO Lui Franciosi stated, “I was very impressed by their Phase I and Phase II-III clinical trial…

Continue Reading